FabiFlu is the first oral favipiravir – approved medication in India for the treatment of Covid-19,is said in a statement. It is a prescription based medication with recommended dose being 1,800 mg twice daily on day one, followed by 800 mg twice daily upto day 14, it added.
Drug firm Glenmark Pharmaceuticals in Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate Covid-19 at a price of about Rs 103 per tablet .
Glenmark will work closely with the government and medical community to make FabiFlu quickly accessible to patient across the country.
